Abstract
Background and Aim Recently new technologies have emerged to improve prevention and control of healthcare-associated infections. Our aim is to verify availability and use of new technologies for infection controllers.
Methods We conducted a survey in infection controllers from the whole state of Rio de Janeiro state, Brazil, by invitation of a social media group, in August 2022. Nine different technologies were evaluated about availability and use. Categoricals and continuous variables were evaluated by the chi-square test and Mann-Whitney U test, respectively. A value of p less than .05 was considered as statistically significant.
Results One hundred-eight persons answered the questionnaire. The mean age was 42.8 years (24-64 years) and 53/108 (49.1%) reported most workload in public hospitals, 45/108 (41.7%) in private hospitals and 10/108 (9.2%) reported the same workload in public and private hospitals. Out of 108, 63% reported teaching activities in his institutions. There was no correlation between the existence of teaching activities and hospital profile (p=0.42). The most common new technology available was molecular biology (PCR) for microbiological samples research for 73/108 (67.6%) participants. The second new technology available was APP for HAI prevention and control for 33/108 (30.6%), 19/108 (17.6%) reported availability of none technology.
Conclusion Molecular biology (PCR) for microbiological samples research was the most common technology available for infection controllers of an important state of Brazil.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was submitted and approved by the Ethics Committee of Faculty of Medicine (Universidade Federal Fluminense), under number 5.563.562 dated from August 4, 2022. A consent statement for the use of data from the each participant included were required.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Address for contact: Rua Marquês do Paraná 303, Centro- Niterói-RJ, Brasil. ZIP-CODE: 24033-900, Email: aricardo{at}id.uff.br
Data Availability
All data produced in the present study are available upon reasonable request to the authors
